Compare Cadila Healthcare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs TORRENT PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE TORRENT PHARMA CADILA HEALTHCARE/
TORRENT PHARMA
 
P/E (TTM) x 32.8 40.5 80.9% View Chart
P/BV x 4.2 9.7 43.4% View Chart
Dividend Yield % 0.8 0.6 130.6%  

Financials

 CADILA HEALTHCARE   TORRENT PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
TORRENT PHARMA
Mar-19
CADILA HEALTHCARE/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs4321,964 22.0%   
Low Rs3061,245 24.6%   
Sales per share (Unadj.) Rs128.6453.4 28.4%  
Earnings per share (Unadj.) Rs18.525.8 71.9%  
Cash flow per share (Unadj.) Rs24.462.3 39.2%  
Dividends per share (Unadj.) Rs3.5017.00 20.6%  
Dividend yield (eoy) %0.91.1 89.4%  
Book value per share (Unadj.) Rs101.5279.2 36.3%  
Shares outstanding (eoy) m1,023.74169.22 605.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.5 81.2%   
Avg P/E ratio x19.962.2 32.0%  
P/CF ratio (eoy) x15.125.8 58.8%  
Price / Book Value ratio x3.65.7 63.4%  
Dividend payout %18.965.9 28.6%   
Avg Mkt Cap Rs m378,170271,513 139.3%   
No. of employees `00012.413.6 91.5%   
Total wages/salary Rs m21,24114,038 151.3%   
Avg. sales/employee Rs Th10,585.05,642.6 187.6%   
Avg. wages/employee Rs Th1,707.81,032.4 165.4%   
Avg. net profit/employee Rs Th1,526.5320.9 475.8%   
INCOME DATA
Net Sales Rs m131,65676,728 171.6%  
Other income Rs m2,011571 352.5%   
Total revenues Rs m133,66777,299 172.9%   
Gross profit Rs m29,73119,831 149.9%  
Depreciation Rs m5,9866,177 96.9%   
Interest Rs m1,9355,038 38.4%   
Profit before tax Rs m23,8219,187 259.3%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m5,3031,254 423.1%   
Profit after tax Rs m18,9874,363 435.2%  
Gross profit margin %22.625.8 87.4%  
Effective tax rate %22.313.6 163.2%   
Net profit margin %14.45.7 253.6%  
BALANCE SHEET DATA
Current assets Rs m84,98150,375 168.7%   
Current liabilities Rs m73,42551,653 142.1%   
Net working cap to sales %8.8-1.7 -527.1%  
Current ratio x1.21.0 118.7%  
Inventory Days Days7592 81.0%  
Debtors Days Days11068 160.4%  
Net fixed assets Rs m133,49383,648 159.6%   
Share capital Rs m1,024846 121.0%   
"Free" reserves Rs m102,83946,397 221.6%   
Net worth Rs m103,86347,244 219.8%   
Long term debt Rs m39,49739,129 100.9%   
Total assets Rs m234,831141,209 166.3%  
Interest coverage x13.32.8 471.4%   
Debt to equity ratio x0.40.8 45.9%  
Sales to assets ratio x0.60.5 103.2%   
Return on assets %8.96.7 133.8%  
Return on equity %18.39.2 197.9%  
Return on capital %18.312.3 148.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40422,103 219.0%   
Fx outflow Rs m11,5935,522 210.0%   
Net fx Rs m36,81116,581 222.0%   
CASH FLOW
From Operations Rs m28,82317,981 160.3%  
From Investments Rs m-57,387-2,413 2,378.4%  
From Financial Activity Rs m18,846-13,145 -143.4%  
Net Cashflow Rs m-7,1052,380 -298.5%  

Share Holding

Indian Promoters % 74.8 71.5 104.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 7.0 118.2%  
FIIs % 5.9 12.6 46.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.8 125.0%  
Shareholders   44,069 26,511 166.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 163 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

It was indeed a volatile trading day for share markets in India today. After staging a gap-up opening, Indian share markets reversed gains.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 21, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS